|

Detection of Brain Metastases Using a Novel Gadolinium-Weighted MRI Sequence: A Prospective Comparison

RECRUITINGSponsored by Region Stockholm
Actively Recruiting
SponsorRegion Stockholm
Started2026-01-28
Est. completion2026-12-31
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07272616

Summary

This study will evaluate a new type of MRI sequence designed to improve the visibility of brain metastases after gadolinium contrast injection. The purpose is to determine whether this novel "gadolinium-weighted" imaging method can detect more or smaller tumors than standard MRI techniques. Participants will undergo a routine brain MRI with contrast, followed by an additional scan using the new method. The goal is to improve diagnostic accuracy without increasing the contrast dose or scan time.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Age 18 years or older
* Scheduled for clinical brain MRI with gadolinium contrast
* Known or suspected brain metastases
* Able to provide informed consent
* Able to lie still for the duration of the MRI examination

Exclusion Criteria:

* Contraindications to MRI
* Known allergy or contraindication to gadolinium-based contrast agents
* Renal impairment (eGFR \< 30 mL/min/1.73m²)
* Pregnant or breastfeeding
* Inability to comply with study procedures

Conditions2

Brain NeoplasmsCancer

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.